Use of liposomal anthracyclines in Kaposi's sarcoma

Susan E. Krown, Donald W. Northfelt, David Osoba, J. Simon Stewart

Research output: Contribution to journalArticlepeer-review

115 Scopus citations


Conventional chemotherapy regimens for the treatment of advanced Kaposi's sarcoma (KS) show limited efficacy and considerable toxicity. Liposomal anthracyclines with potential utility in KS include pegylated liposomal doxorubicin (Doxil/Caelyx [PLD]), daunorubicin citrate liposome (DaunoXome [DNX]), and nonpegylated liposomal doxorubicin (Myocet [NPLD]). Preclinical data showed that pegylated liposomes accumulate preferentially in highly vascularized KS lesions. In randomized clinical trials, PLD induced higher response rates than did the conventional combination chemotherapy regimens, bleomycin + vincristine (BV) and BV + conventional doxorubicin (ABV); DNX produced a response rate comparable to that of ABV. NPLD has not been compared with conventional chemotherapy for KS. PLD and DNX were associated with less toxicity compared with BV or ABV, including less alopecia and fewer gastrointestinal and neurologic side effects. Grade 3/4 myelosuppression was common with both PLD and DNX; stomatitis and infusion reactions occurred with PLD treatment, but hand-foot syndrome was relatively infrequent in the dose schedules used for KS. Health-related quality of life was improved in several domains in patients treated with PLD or DNX compared with ABV.

Original languageEnglish (US)
Pages (from-to)36-52
Number of pages17
JournalSeminars in oncology
Issue numberSUPPL. 13
StatePublished - Dec 2004

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Use of liposomal anthracyclines in Kaposi's sarcoma'. Together they form a unique fingerprint.

Cite this